Tests tirofiban with tenecteplase in people with acute ischemic stroke
Tests tirofiban alongside tenecteplase in adults having an acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
Key facts
- Where
- Chifeng, Chuzhou, Dalian, Ganzhou, Huaihua, Huanggang, Ji’an, Jiujiang, Longyan, Nanchang, Nanning, Shaoyang, Songyuan, Xiangtan, Yichang, Yichun, Yingtan, and Yueyang, ChinaSee the 38 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute ischemic stroke who were given tenecteplase and then did not improve or got worse within 4-24 hours. It tests early tirofiban.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute ischemic stroke, 4-24 hours after tenecteplase. Symptoms have not changed much, or have worsened, or have gone up and down. NIHSS score of 4 points or more before randomization.
- Earlier treatment
- Must have had intravenous thrombolysis with tenecteplase for the stroke 4-24 hours earlier.
Main reasons for not taking part
- Bleeding in the brain seen on CT or MRI after thrombolysis
- Blocked large brain or neck artery seen on CTA/MRA/DSA
- Confirmed or suspected stroke caused by a clot from the heart
- Platelet count lower than 100×10^9/L, or kidney filtration rate below 30 mL/min
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Where in China
- Zhongmeng Hospital of Hexigten BannerChifeng, ChinaContact: Dan LiTaking people
- Mingguang People's HospitalChuzhou, ChinaContact: Zongliang Li,Taking people
- Dalian Municipal Central HospitalDalian, ChinaContact: Zhongjun ChenTaking people
- Ganzhou Municipal HospitalGanzhou, ChinaContact: Hongwen LiuTaking people
- Ganzhou People's HospitalGanzhou, ChinaContact: Guoyong Zeng, MDTaking people
- Nankang TCM HospitalGanzhou, ChinaContact: Fangwei LiTaking people
- People's Hospital of Anyuan CountyGanzhou, ChinaContact: Hong ZhangTaking people
- People's Hospital of Chongyi CountyGanzhou, ChinaContact: Xunwei Lv,Taking people
- People's Hospital of Dayu CountyGanzhou, ChinaContact: Huashi Liu,Taking people
- People's Hospital of Ganxian DistrictGanzhou, ChinaContact: Weihua Hu,Taking people
- People's Hospital of Quannan CountyGanzhou, ChinaContact: Bin ChenTaking people
- People's Hospital of RuiJin CityGanzhou, ChinaContact: Ruize ZhouTaking people
- People's Hospital of Shangyou CountyGanzhou, ChinaContact: Yi YinTaking people
- People's Hospital of Shicheng CountyGanzhou, ChinaContact: Gengxiang XiaoTaking people
- People's Hospital of Xinfeng CountyGanzhou, ChinaContact: Yan ShiTaking people
- People's Hospital of Xunwu CountyGanzhou, ChinaContact: Donghuan MeiTaking people
- People's Hospital of Yudu CountyGanzhou, ChinaContact: Zhiyong Xie,Taking people
- Second Hospital of Xingguo CountyGanzhou, ChinaContact: Shanggui YuanTaking people
- Second People's Hospital of Yudu CountyGanzhou, ChinaContact: Xiaoyu Guan,Taking people
- The People's Hospital of Ningdu CountyGanzhou, ChinaContact: Hairong Hu,Taking people
- Traditional Chinese Medicine Hospital of Xingguo CountyGanzhou, ChinaContact: Shuiping LiangTaking people
- Traditional Chinese Medicine Hospital of Yudu CountyGanzhou, ChinaContact: Jinchang TanTaking people
- Hunan Xupu Chengnan HospitalHuaihua, ChinaContact: Bo WangTaking people
- Huangmei People's HospitalHuanggang, ChinaContact: Junfeng ShiTaking people
- Ji'an Central People's HospitalJi’an, ChinaContact: Yi ChenTaking people
- People's Hospital of Wan'an countyJi’an, ChinaContact: Bin LiuTaking people
- Affiliated Hospital of Jiujiang UniversityJiujiang, ChinaContact: Zhongbin XiaTaking people
- Longyan People´s Hospital, Longyan CityLongyan, ChinaContact: Yuqin DengTaking people
- Jiangxi Provincial People's HospitalNanchang, ChinaContact: Wenfeng CaoTaking people
- The Second Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaContact: Deyan Kong, MDTaking people
- People's Hospital Of ShaodongShaoyang, ChinaContact: Limin ShenTaking people
- Songyuan Jilin Oilfield HospitalSongyuan, ChinaContact: Ying JinTaking people
- Shaoshan People's HospitalXiangtan, ChinaContact: Zhenhua XiaoTaking people
- Xiangtan Central HospitallXiangtan, ChinaContact: Guangxiong YuanTaking people
- Yiling People's Hospital of Yichang cityYichang, ChinaContact: Hailong XuTaking people
- People's Hospital of YichunYichun, ChinaContact: Xinbo DengTaking people
- Yingtan People's HospitalYingtan, ChinaContact: Jingjing LiuTaking people
- Hunan University of Medicine Affiliated Pingjiang HospitalYueyang, ChinaContact: Xiang ZengTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital of Guangxi Medical University
- Trial code
- NCT05604638
- Record updated
- 24 December 2025
- Original description
The purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.Read full original descriptionShow less
Safety and Efficacy of Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
The purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.
Inclusion: Age ≥ 18 years old; Within 4-24 hours after intravenous thrombolytic therapy with tenerplase for acute ischemic stroke, there was no significant change in symptoms compared to the baseline (defined as an increase or decrease of 0 or 1 point in the NIHSS score), and neurological function deteriorated (defined as an increase of ≥ 2 in the NIHSS score compared to the baseline) Fluctuations in neurological function (defined as an increase of 4 points or more in the NIHSS score compared to the baseline and then a decrease of 4 points or more); NIHSS ≥ 4 points before randomization; The patient or their family members sign a written informed consent form.
Exclusion: Prior neurological or psychiatric illness that prevents assessment of neurological function; Intracranial hemorrhage was confirmed by CT or MRI after intravenous thrombolysis and before randomization; Renal insufficiency, glomerular filtration rate < 30 mL/min; Allergic to tirofiban, nickel, titanium or their alloys; Pre-existing bleeding disease, severe heart, liver, or kidney disease, or sepsis; Life expectancy of any advanced disease < 6 months; Confirmed or suspected cardioembolic stroke mechanisms, including any of the following: documented cardiac sources of thromboembolism: chronic or paroxysmal atrial fibrillation, rheumatic mitral stenosis, prosthetic heart valves, infective endocarditis, intracardiac thrombus or implanted prosthetic material, dilated cardiomyopathy (left ventricular ejection fraction <40%), or spontaneous echo contrast in the left atrium; other laboratory-confirmed embolic sources: patent foramen ovale with concomitant atrial septal aneurysm, or cryptogenic stroke with a CHADS-VASC score ≥ 2 indicating high thromboembolic risk; Blood platelet count was lower than 100×10\^9/L; CTA/MRA/DSA showed occlusion of the internal carotid artery, middle cerebral artery M1, M2 or M3 segment, anterior cerebral artery A1, A2 or A3 segment, posterior cerebral artery P1, P2 or P3, vertebral or basilar artery; Pregnant or lactating women; Brain tumors with a space-occupying effect on imaging (other than micromeningiomas); Intracranial aneurysm, arteriovenous malformation; Participating in other clinical trials.